Can I not stop taking Mobosetinib/Mobosetinib once I take it?

Mobocertinib/Mobocertinib is a targeted drug targeting epidermal growth factor receptor (EGFR) mutations. It is mainly used to treat patients with small cell lung cancer carrying specific EGFR mutations. Like many targeted therapy drugs, the use of mobosertinib needs to be under the guidance of a doctor, and patients are often concerned about discontinuation of the drug when taking it.

Mobosetinib is usually taken to control the disease and prolong life. Mobosetinib belongs to the kinase inhibitor class of drugs. It works by blocking the activity of abnormal proteins, which are signals for cancer cell reproduction. This helps stop or slow the spread of cancer cells and may help shrink tumors. When a patient is taking this drug, if the drug can effectively inhibit tumor growth and the patient can tolerate the side effects of the drug, continued use is usually recommended. This is because the efficacy of most targeted drugs is to continue to work. If the drug is stopped midway, it may lead to tumor progression or even recurrence.

The decision to discontinue medication is not an easy one and often requires the consideration of multiple factors. For example, the patient's disease status, tumor response, tolerance, and potential side effects. If a patient experiences serious adverse reactions during treatment, the doctor may consider adjusting the dose or temporarily discontinuing the drug. However, in this case, the doctor will closely monitor the patient's condition and evaluate whether the medication can be restarted.

In addition, for some patients, as treatment progresses, the tumor may become drug-resistant, and at this time the doctor may recommend changing to other treatment options. In this case, although mobosertinib may not be continued, this does not mean that the patient must discontinue all treatment options.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC9898076/